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http://dx.doi.org/10.1016/j.kjms.201Abstract Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are widely
prescribed as cholesterol-lowering drugs. Statins have recently been found to have pleiotropic
effects that are independent of their lipid-lowering properties. Phosphorylation of serine, thre-
onine, and tyrosine residues of functional proteins are considered to be important in the endo-
thelial signaling cascade. In this study, protein phosphorylation status in human umbilical vein
endothelial cells (ECs) after rosuvastatin treatment was examined. The proteins were collected
from rosuvastatin-treated ECs and then the phosphorylated peptides purified by a Fe3þ-immo-
bilized metal-affinity chromatography bead system were examined by liquid chromatographye
tandem mass spectrometry analysis. Alterations of the phosphorylation status of proteins
were noticed after rosuvastatin treatment. There were 277 and 530 phosphorylated proteins
identified from the control and rosuvastatin-treated ECs, respectively. Among those proteins,
T78, in addition to S156 of the Ras-GTPase-activating protein, was phosphorylated after rosu-
vastatin treatment. Rosuvastatin reduced the phosphorylation of Y455 in HSP90 protein.
Decreased phosphorylation of T211 with a concurrent increase in the T291 phosphorylation ofBiomedical Sciences, Academia Sinica, 128 Section 2, Academia Road, Nankang, Taipei, Taiwan.
ica.edu.tw (L.D. Wang).
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348 B. Huang et al.Akt1 was observed under rosuvastatin treatment. Increased S633 phosphorylation was detected
in endothelial nitric oxide synthase. Western blot analysis further showed an earlier and greater
S633 phosphorylation than that of S1177 in endothelial nitric oxide synthase after rosuvastatin
treatment. Changes in the phosphorylation status of these proteins may alter the protein’s func-
tion and affect endothelial physiology. The current study provides new insights leading to
a better understanding of the pleiotropic effects of statins on the vascular system.
Copyright ª 2012, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reduc-
tase inhibitors, commonly called statins, were first devel-
oped to lower total serum cholesterol and to improve the
serum lipid profile. The cholesterol-independent pleio-
tropic effects of statins that have been extensively
researched include improved endothelial function, reduced
oxidative stress, prevention of platelet aggregation, and
stabilization of atherosclerotic plaques [1,2]. Increasing
evidence suggests that protein phosphorylation promotes
statin-induced pleiotropic effects. Statins induce phos-
phorylation of Mdm2 and attenuate the p53 response to
DNA damage [3]. Moreover, statins phosphorylate the serine
(S) at S1177 and S633 of endothelial nitric oxide synthase
(eNOS) through the phosphatidylinositol-3-kinase/protein
kinase B or AMP-activated protein kinase (AMPK) pathway
and thus trigger cardioprotective signaling via nitric oxide
[4e6]. Furthermore, statins increased the expression of
heme oxygenase-1, which is involved in stress response [7].
Phosphorylation of protein tyrosine phosphatase, which is
required for the normal activation of extracellular signal-
regulated protein kinases in multiple-receptor tyrosine
kinase signaling pathways, is increased after rosuvastatin
treatment [8]. This implies that protein phosphorylation is
an early response signal that contributes to vascular
homeostasis. However, there is currently no known direct
link between protein phosphorylation and statin-induced
pleiotropic effects.
Currently, six statin compounds are available in the
market as cholesterol-lowing drugs; the pharmacokinetics
of these compounds differs due to differences in their
hydrophobicity. Rosuvastatin exhibits hydrophilic proper-
ties and possesses the lowest inhibition coefficient [9]. It
exerts protective effects on tissues by suppressing the
release of inflammatory mediators such as monocyte
chemotactic protein-1 (MCP-1), transforming growth
factor-beta 1, interleukin-1 beta, and tumor necrosis
factor-alpha [10]. Rosuvastatin also reduced monocyte
adhesion, possibly through the decreased expression of
intercellular adhesion molecule-1, MCP-1, interleukin-8,
interleukin-6, and COX2 in tumor necrosis factor-alpha-
treated endothelial cells (ECs) [11]. Rosuvastatin signifi-
cantly reduced DNA damage by H2O2 [12]. Pretreatment of
mice with rosuvastatin curbed myocardial necrosis after
ischemia and reperfusion [13]. Compared to other statins,
rosuvastatin is weakly absorbed by ECs. However, it upre-
gulates eNOS expression and activity via the phosphoryla-
tion that provides superior endothelial protection, more
than that by other statins [14].The purpose of this study was to demonstrate the
dynamic phosphoproteome in rosuvastatin-treated ECs.
Using the immobilized metal-affinity chromatography
(IMAC) method to enrich the phosphopeptides from cell
lysate [15], we obtained 530 phosphoproteins with high
sequence identities. Dynamic changes in phosphorylation
status after rosuvastatin treatment were observed in
some proteins, including Ras-GTPase-activating protein,
heat shock protein 90 (HSP90), Akt1, and eNOS. Western
blot confirmed that S633 was phosphorylated earlier and
to a greater extent than S1177 in eNOS from ECs after
rosuvastatin treatment. The current study provides
a global profile of rosuvastatin-induced protein phos-
phorylation, which provides a basis for further studies




ECs were isolated from human umbilical cords as described
previously [16]. The procedure conformed to the principles
outlined in the Declaration of Helsinki for the use of
human tissue or subjects. ECs were cultured in M199
medium supplemented with fetal bovine serum (20%),
streptomycin (100 mg/mL), and penicillin (100 U/mL). The
medium was then replaced with M199 medium containing
2% fetal bovine serum, and the ECs were incubated over-
night prior to rosuvastatin (AstraZeneca, Taipei, Taiwan)
treatment.
Cell lysis and trypsin digestion
After rosuvastatin treatment, the ECs were washed with
cord buffer [NaCl (0.14M), KCl (4 mM), glucose (11 mM),
HEPES (10 mM, pH 7.4)] and then lysed with lysis buffer
[HEPES (250 mM, pH 7.7), EDTA (1 mM), neocuproine
(0.1 mM), 3-[(3-Cholamidopropyl)dimethylammonio]-1-pro-
panesulfonate (CHAPS, 0.4%, w/v), protease inhibitor
(0.2%, v/v), and Phosphatase arrest (G-Bioscience, MO,
USA)]. After centrifugation, detergents and salts in the
protein supernatant were removed by spin column (G-
Bioscience). The protein concentrations were determined
by bicinchoninic acid assay reagent (Thermo Fisher Scien-
tific, IL, USA). Protein lysates (50 mg) were mixed and
adjusted to 100 mL with 25 mM trimethylammonium bicar-
bonate buffer. The samples were then incubatedwith 1 mg of
modified trypsin (Promega, Madison, WI, USA) for 16 hours.
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An immobilized metal ion affinity chromatography (IMAC)
column (5 cm 500 mm i.d., PEEK tubing,which is an attached
component of spin column produced by Qiagen) was packed
with nickel nitrilotriacetic acid (Ni-NTA) resin from the spin
column (Qiagen,Hilden,Germany).Beforeuse,Ni2þ ionswere
removed with 100 mL of 50 mM EDTA in 1M NaCl, and then
incubated with 100 mL of 200 mM FeCl3. The peptide sample
was reconstituted in100mL loadingbuffer (6%acetic acid, v/v,
pH 3.0) and loaded into the Fe-IMAC column. The unbound
peptides were washed out with 100 mL washing solution
[acetonitrile (25%, v/v) and acetic acid (6%, v/v; pH 3.5)]. The
phosphopeptides were eluted from the IMAC column with
100 mL of 200 mM NH4H2PO4 (pH 4.4). The eluted peptide
sample was then desalted with a ZipTip (Millipore, Billerica,
MA, USA) and dried under a vacuum.
Nano-liquid chromatographyetandem mass
spectrometry analysis
The purified phosphopeptide samples were reconstituted in
sample buffer [formic acid, (0.5%, v/v)] and analyzed by
nano-liquid chromatographyetandem mass spectrometry
on a Thermo LTQ XL ion trap mass spectrometer (Thermo
Fisher Scientific, IL, USA). A split-flow configuration of high-
performance liquid chromatography (Agilent1100 HPLC
system; Hewlett-Packard, Palo Alto, CA, USA) was used for
online sample separation. The sample was injected into
a homemade capillary trap column (2 cm  100 mm i.d.) and
packed with Magic C18AQ reversed-phase material (5 mm,
200 A˚, Michrom BioResources, CA, USA). The peptides were
separated using a 13 cm  75 mm i.d. capillary column
(10 mm electrospray tip, packed with Magic C18AQ;
Michrom BioResources), and eluted with a linear gradient of
0e80% buffer A (formic acid, 0.1%, v/v) and buffer B (for-
mic acid, 0.1%, v/v in acetonitrile) for 75 minutes at
300 nL/minute. The mass spectrometer was run in a top five
configuration with one mass spectrometry scan followed by
five MS/MS scans. Peptide fragmentation by collision-
induced dissociation was performed automatically using
a dynamic data-dependent method.
Database search
Sequence identification was performed on a Mascot server
(in-house, v 2.2, Matrix Science, London, UK). The data sets
were searched against the non-redundant protein database
of the National Center for Biotechnology Information using
the following constraints: trypsic peptides with up to two
missed cleavage sites; 2.0 Da mass tolerances for mass
spectrometry; and 0.8 Da mass tolerances for MS/MS frag-
ment ions. Modifications specified in the search were
differential carbamidomethylation in cysteine, differential
oxidation in methionine, and differential phosphorylation
in serine, threonine (Thr, T), and tyrosine (Tyr, Y). To
evaluate the false discovery rate of identification, the data
sets were also searched against a decoy database created
by Mascot (false discovery rate <1%). The peptides that
contained phosphorylated Ser/Thr/Tyr sites were deter-
mined with a mass shift of 80 Da.Western blot
The phosphorylation on the S633 and S1177 residues in
eNOS, which was identified in the mass spectrometric
assay, was further verified by Western blot. The blotted
membrane was incubated with monoclonal antibody
(1:3000; Cell Signaling Technology Inc., Danvers, MA, USA).
The hybridized nitrocellulose membrane was developed
with SuperSignal West Femto reagent (Thermo Fisher
Scientific, IL, USA) and exposed to the radiograph. The film
was scanned by a digital scanner (Microtek, International
Inc., Taipei, Taiwan), and the relative protein density was
calculated by PhotoImpact X3.Results
Identification of rosuvastatin-induced
phosphoproteome
In the present study, the rosuvastatin-induced phospho-
proteome was investigated according to the flowchart in
Fig. 1. It is notable that we used a polymer-filled spin
column to remove inorganic salts and detergents. After
trypsin digestion and IMAC enrichment, 277 and 530 phos-
phorylated proteins were identified from ECs after control
and rosuvastatin treatment, respectively. Among those, 76
phosphorylated proteins were simultaneously shown on
both treatments (Supplementary Table 1). Those phospho-
proteins in each treatment (control/rosuvastatin) were
classified according to their physiological functions (Fig. 2):
8.7%/9.6% cytoskeleton proteins; 6.5%/10% nuclear
proteins; 8.7%/11.7% transcription factors; 9%/10% HSPs;
24.2%/22.6% proteins involved in energy production; 6.5%/
11.9% proteins involved in metabolism; and 36.4%/24.2%
others.
Rosuvastatin-induced dynamic shifts of
phosphorylated residues on proteins
Further analysis of the MS/MS data revealed changes in
phosphorylation sites in the peptide sequences (Fig. 3). An
additional phosphorylated T78 was detected in the Ras-
GTPase-activating protein after rosuvastatin treatment.
Rosuvastatin treatment decreased the Y455 phosphoryla-
tion in HSP90 protein. In Akt1, T291 was phosphorylated
instead of T211. For eNOS, in addition of the S1177, an
increased S633 phosphorylation was observed.
Rosuvastatin induced earlier S633 phosphorylation
than S1177 in eNOS
As shown in Fig. 4, the phosphorylation levels of eNOS S633
and S1177 were verified using monoclonal antibodies. After
rosuvastatin (10 mM) treatment for 0.5 hours and 24 hours,
there was a three-fold and approximately 15-fold increase
in the S633 phosphorylation, respectively, when compared
to controls were observed. In addition, examination of the
phosphorylation status revealed that S633 was phosphory-
lated earlier than S1177 after rosuvastatin treatment.
Figure 1. Flowchart of the mass spectrometric technique applied in elucidating the statin-regulated phosphoproteome. Human
umbilical vein endothelial cells with either rosuvastatin or control treatment were lysed. The protein lysates were digested by
trypsin, and the resulting peptides containing phospho groups (PO4) were conjugated by Fe3þ-IMAC magnetic beads. The purified
phosphorylated peptides were subjected to liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis, and the
phosphorylated sites were determined.
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Statin-induced pleiotropic effects that are independent of
their cholesterol-lowering character remain a key issue for
clinical and basic research. Ser/Thr/Tyr phosphorylation is
regarded as an important posttranslational modification
during the signaling cascade [17]. In the present study, we
found that rosuvastatin treatment lead to a nearly two-fold
increase in the overall phosphorylated proteins in ECs
compared to the controls. Moreover, those proteins
exhibited different phosphorylation sites. Changes in
phosphorylation sites were illustrated in four proteins that
were known to be involved in regulating eNOS activityFigure 2. Functional classification of the rosuvastatin-regulated p
categorized into seven groups according to the annotated functio
percentage of each protein are indicated.(Fig. 3). In addition to the HMG-CoA reductase inhibition
that decreases cholesterol synthesis, statins inhibit the
isoprenylation of small GTPases such as Ras, Rho, Rab, and
Rap [18]. Ras-GTPase-activating protein is a target for the
protein tyrosine kinases of both the receptor and cyto-
plasmic classes, and may serve to integrate Ras signaling
pathways [19]. It is possible that phosphorylation of T78 in
the GTPase-activating protein may modulate activation of
the Ras signaling pathway, which may contribute to the
pleiotropic effects of statins.
Nitric oxide, a gaseous molecule, significantly affects
vascular tone. It is considered to be significantly involved in
mediating the pleiotropic effects of statins [2,20]. In thishosphoproteome. The identified phosphorylated proteins were
ns by Ingenuity Pathway Analysis. The total number and the
Figure 3. Rosuvastatin regulates dynamic phosphorylation on protein residues. Following a Mascot in-house software algorithm,
four proteins were shown to have dynamic variations of phosphorylated peptides on proteins. The asterisk indicates the locations of
phosphorylated Ser/Thr/Tyr residues. Ac represents the accession number in the National Center for Biotechnology Information
database.
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signaling proteins involved in nitric oxide generation, are
modulated by posttranslational modification. With rosu-
vastatin treatment, the number of phosphorylated HSPs
increased from 25 to 53 (Fig. 2). Among these HSPs, HSP90
is known to enhance eNOS activity [21]. In this study, we
observed a decrease of Y455 phosphorylation in HSP90.
Whether this decreased phosphorylation affects its stimu-
lation effect on eNOS remains unclear. Akt is a part of the
PI3K-Akt-eNOS signaling cascade and has shown a dynamic
phosphorylation response to rosuvastatin treatment. It is
well known that Akt is activated by phosphorylation at
S473, and this is essential for the subsequent activation of
eNOS by phosphorylation at S1177 [22]. Another report
showed that treatment with pitavastatin induced Akt
phosphorylation at S473 [4]. Although phosphorylation at
S473 was not shown in the present MS/MS data,Figure 4. Rosuvastatin enhanced phosphorylation of eNOS S635 a
with rosuvastatin (10 mM) for 0.5, 6.0, and 24.0 hours were separate
and subjected to Western blotting with antibodies against eNOS (1
(1:5000). (B) The relative fold changes are shown by mean  st
replications. The changes were individually compared to the contro
differences, and indicated as a, b, and c.phosphorylation of T291 instead of T211 of Akt was
observed after rosuvastatin treatment. It is unclear
whether this changed pattern of phosphorylation can lead
to alterations in the enzymatic activities of Akt.
Phosphorylation of either S1177 or S633 significantly
activates eNOS and increases NO production [5,23]. From
the mass spectrometry data in this study, we further veri-
fied the phosphorylation of both activation sites and
showed that S633 exhibited an earlier response to rosu-
vastatin treatment than that by S1177. Furthermore, the
increase in eNOS phosphorylation was sustained for at least
24 hours. With rosuvastatin treatment, S633 appears to be
a major phosphorylation site for nitric oxide production. It
has been suggested that S633 phosphorylation is more
potent than S1177 phosphorylation in augmenting eNOS-
derived nitric oxide production. Both Akt and AMPK can
phosphorylate S633 in eNOS when ECs are subjected tond S1177. (A) Protein lysates (40 mg) extracted from ECs treated
d by sodium dodecyl sulfate polyacrylamide gel electrophoresis
:3000), peNOS S1177 (1:3000), peNOS S633 (1:500), and b-actin
andard error as compared to control treatments from three
l by Fisher’s least significant difference for significant (p < 0.05)
352 B. Huang et al.shear stress [23,24]. AMPK phosphorylation of S633 in eNOS
is required to prime SIRT1-induced deacetylation of eNOS
to promote nitric oxide production, indicating an athero-
protective flow via AMPK and SIRT1 to increase nitric oxide
bioavailability in the endothelium [25]. Further investiga-
tion of the interrelationship between the AMPK pathway
and phosphatidylinositol-3-kinase/protein kinase signaling
to eNOS activation in rosuvastatin-mediated car-
dioprotection is necessary.
The pharmacology of statins has been under compre-
hensive investigation because of its pleiotropic effects
which contribute to improved vascular functions during
diabetes-induced complications [2]. In this study, with the
help of advanced proteomic techniques, we have examined
global phosphoproteome and our study provides a basis for
further phosphorylation profiling that may contribute to the
understanding of the pleiotropic effects of statins.
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